Our recent work demonstrated that common cardiovascular progenitor cells are characterized and induced by the expression of the transcription factor mesoderm posterior1 (MesP1) in vertebrate embryos and murine embryonic stem cells. As the proliferative potential of stem cell-derived cardiomyocytes is limited, it is crucial to understand how MesP1 expression is mediated in order to achieve reasonable and reliable yields for novel stem cell-based therapeutic options. As potential upstream regulators of MesP1, we therefore analysed Eomes and Brachyury(T), which had been controversially discussed as being crucial for cardiovasculogenic lineage formation.
Introduction
The cardiovascular system is the first organ system to develop in vertebrates. The derivation of myocardial cells from angioblasts and endothelial cell clusters demonstrates that the heart and vessels arise from common cardiovascular progenitor cells. 1 Thereby, lateral plate mesodermal cells start expressing the basic helix-loop-helix (bHLH) transcription factor mesoderm posterior1 (MesP1) which is highly specific for all cardiogenic and several vasculogenic regions giving rise to the dorsal aorta, intersomitic, and cranial vessels. 2 -4 MesP1 expressing cells therefore are currently regarded as the first largely specific population of multipotent cardiovascular progenitor cells capable to form all components required to build up the heart. Corresponding cardiovascular progenitor cells are also developing from pluripotent cell lines such as embryonic stem (ES) and induced pluripotent stem cells as well as spermatogonial or parthenogenetic stem cells. 5 In addition, direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors has been described recently. 6 In this regard, we and others have shown that MesP1 not only represents an early cardiovascular marker, but is rather a key regulator even sufficient to induce cardiovasculogenesis in pluripotent cells as well as in vertebrate embryos. 7 -9 Future use of stem cell-derived cardiomyocytes will be highly dependent on the appropriate specified cellular subtypes of which a number exist in the heart. Therefore, in a first approach of 'genetic forward programming' of stem cells, we recently demonstrated that Nkx2.5 similar to MesP1 is sufficient to enhance cardiogenesis 10 . However, MesP1 led to an enrichment of 60% multipotent early/intermediate type cardiomyocytes, whereas Nkx2.5 yielded 80% ventricular cells and in contrast to MesP1, no increase in the endothelial lineage within the cardiovasculogenic mesoderm was observed. 10 Yet, the regulation of MesP1 expression itself is totally unclear and there have been contradictory reports with respect to the origin of cardiovascular precursors in ES cells first described as PDGFR-VEGFR2 double-positive cells by Sakurai et al.
11
and recently extended to a PDGFRa-VEGFR2-CXCR4 triple-positive population. 12 In agreement with these findings, we have previously shown that MesP1 induces the formation of VEGFR2 (Flk-1) positive cells. 7, 10 Izumi et al. had described the appearance of PDGFR-VEGFR2
double-positive cells almost completely suppressed after Eomes knockdown. Yet, this population representing the source of the cardiovascular cells remained greatly unaffected after Brachyury(T) knockdown in their experimental settings. 13 In strong contrast to this loss of function approach, Kattman et al. 14 ascribe the cardiovasculogenic cells to a population double positive for Brachyury(T) and Flk-1/VEGFR2. We therefore have analysed the regulation of the MesP1 promoter with respect to direct upstream factors and to its potential to demarcate the earliest common cardiovascular progenitors.
Methods

ES cell culture and generation of stable clones
We obtained the human Brachyury and Eomesodermin cDNAs from Imagenes (Berlin, Germany) in pCMV-Sport6 and generated stable ES cell clones via electroporation as described. 7, 10 pEGFP-N1 served as a control transfection plasmid in non-Eomesodermin/Brachyury(T) overexpressing cells. Thereby, electroporation and isolation of stable clones using the murine ES cell line GSES were performed according to standard protocols with minor modifications: 15 5 mg non-linearized vector was used for electroporation (240V/500 mF) of 5 × 10 6 GSES cells. Transgenic ES cells were grown in high glucose Dulbecco's modified Eagle medium supplemented with 10% heat-inactivated ES qualified foetal calf serum, 2 mM L-glutamine, 50 U/mL penicillin, 50 mg/mL streptomycin, 1× nonessential amino acids, 0.4 mg/mL GENETICIN (G418) (all reagents GIBCO BRL, Germany), and 0.1 mM b-mercaptoethanol (Sigma, Germany). They were kept undifferentiated under feeder free conditions by addition of 1000 units/mL purified recombinant mouse leukaemia inhibitory factor (ESGRO; Life Technologies, Inc., Grand Island, NY, USA). Cells were maintained at 378C in a humidified atmosphere of 5% CO 2 /95% air. Monolayers were passaged by trypsinization at confluence of 70 -80%. For fluorescence activated cell sorting (FACS) differentiated cells were dissociated using phosphate buffered saline (PBS) containing 5 mM EDTA as described below. In vitro differentiation was initiated as follows: GSES cells were harvested with 0.25% trypsin-EDTA and dissociated cells were transferred to bacteriological dishes at a density of 2 × 10 5 ES cells/mL in ISCOVE's modified Eagle medium (Sigma) supplemented with 10% heat inactivated foetal calf serum, 2 mM L-glutamine, 50 U/mL penicillin, 50 mg/mL streptomycin, 1× non-essential amino acids (all reagents Life Technologies, Inc.), and 450 mM a-monothioglycerol (Sigma). After 2 days, Embryoid bodies (EBs) were transferred to new medium. At Day 6, EBs with a similar size were plated onto gelatin-coated tissue culture dishes. The growth medium for the attached differentiation cultures was changed every day.
Flow cytometry
For FACS analyses detecting enhanced green fluorescent protein (EGFP) expression, the cells were dissociated in PBS containing 5 mM EDTA for 15 min at 378C after washing them twice in calcium-free PBS. Subsequently, the cells were spinned down at 500 g for 3 min in an Eppendorf centrifuge and resuspended in 100 mL ice-cold PBS containing 2% bovine serum albumine. For FACS analyses of CD4 purified cells and CD31 positive cells, the protocol included an incubation in PE-conjugated secondary antibodies (BD Pharmingen or Miltenyi-Biotech; suppliers' protocol) before measuring. PE-conjugated IgG 2a k served as isotype controls. FACS analyses for intracellular proteins were performed as previously described 16 using the primary antibodies and a PE-conjugated secondary antibody (BD Pharmingen). For isotype controls, purified IgG 1 k was used. All FACS analyses for in vivo fluorescence as well as surface and intracellular antigens were performed with an Epics XL (BeckmanCoulter) using the evaluation programme EXPO32ADC.
Confocal analyses
Immunostaining was performed according to standard protocols as described. 7, 10, 15 EB outgrowths seeded on gelatinized 12 mm glass coverslips were rinsed with PBS fixed for 20 min at room temperature with 3.7% formaldehyde and neutralized with 50 mM glycine. The cells were permeabilized using 0.4% Triton X-100 in PBS and incubated with the primary antibody in a humidified chamber at 378C for 2 h. After washing with 0.4% Triton X-100 and PBS, secondary Cy3-conjugated antibody was added and the specimen was incubated for 2 h at 378C. Finally, the cells were washed and mounted with Mowiol (Calbiochem, Germany).
qRT-PCR
Quantitative real-time-polymerase chain reaction (PCR) was performed using RNA isolated from 200 to 250 pooled EBs collected at Days 0, 2, and 6 of differentiation via the Rneasy-Kit (Qiagen). First-strand cDNA was synthesized at 378C from 2 mg RNA with Alfalfa mosaic virus reverse transcriptase (Amersham) and random hexamer primers. Realtime PCR was performed with an iCycler and the MyiQ detection system (Biorad) using the IQ Syber Green Super Mix kit (Biorad). Primers were designed using the DNA Star software and the specificity of each primer pair was confirmed by agarose gel electrophoresis. The annealing temperature was 578C for all primer pairs and the amplified murine cDNA fragments corresponded to 174 -279 bp of hBrachyury(T), to 943 -1095 bp of hEomesodermin, to 800 -974 bp of mMesP1, to 1326-1476 bp of Mef2c, to 836 -974 bp of mBrachyury(T), to 641 -1058 bp of mGATA-4, to 1 -122 bp of hDCD4, to 64 -189 bp of mH4, and to 812-934 bp of m GAPDH. All samples were analysed in duplicates and total RNA pooled from undifferentiated and differentiated ES cells. Murine hearts were used as control and to generate a standard curve for markers analysed. As a negative control, total RNA from each of the samples was run without reverse transcriptase. No signal was detected after 40 PCR cycles in the absence of reverse transcriptase, indicating that all samples were free of DNA contamination. In addition, no signal was detected when reverse transcriptase was added but RNA template was not, indicating that there was no contamination from exogenous RNA or DNA. The standard curve for all genes displayed an increase in one threshold cycle for each bisection of template concentration. Evaluation of relative gene expression levels was performed based on the DC T method. Factors of changes in relative mRNA expression levels were calculated using GAPDH as a reference gene whereby the expression value in control cells was defined as 1.
shRNA knockdown
For stable knockdown of the endogenous murine MesP1 mRNA, the BLOCK-IT system (Invitrogen) was used for Zeocin-based ES cell clone selection according to the supplier's manual. Thereby, the following oligonucleotides were used for initial plasmid generation (loop sequences shown in bold): ′ -GATGT AATACCAGACACCAGG-3 ′ ; lower primer: 5 ′ -GGATAACTTAGTGA CTCCCCG-3 ′ ). qPCR with the precipitates was performed as described above omitting the initial reverse transcriptase steps. All ChIP samples were standardized for unspecific precipitation using the primers for GAPDH described above.
Electrophoretic mobility shift assay
Electrophoretic mobility shift assay (EMSA) was performed according to the manufacturer's protocol (Pierce; Rockford, IL, USA) using nuclear extracts from transfected cells. Oligo sequences used for labelled EMSA probes and 100× specific competition were: hMesP-1 (21.5 kb): GCTGGGATTACAGGTGTGAGCCACCGCGCC; For unspecific 100× competition oligos were: hMesP-1us (21.5 kb): GCTGGGATTACag gaaaaaGCCACCGCGCC; lower case letters represent mutations in the T responsive consensus element.
Whole-mount in situ hybridization
For whole-mount in situ hybridization mouse embryos were processed as described previously. 17 Animals were grown according to the European Union Directive 2010/63/EU. Pregnant females were sacrificed by cervical dislocation. This procedure does not require approval by the local Ethics Commision. The murine MesP1 antisense probe corresponded to 31 -701 bp of the mMesP1 ORF, the murine Brachyury(T) antisense probe contained the full-length ORF.
Generation of the pMesP1 promoter plasmid
The human 3.4 kb MesP1 promoter was amplified from human genomic DNA via proof reading PCR using Pfu-Polymerase (Stratagene). Primers for cloning of the MesP1 promoter fragment contained XhoI and AgeI restriction sites. Subsequently, the PCR product was inserted into pEGFP (Clontech) after digestion with these two enzymes. In detail the primers were: 5 ′ -GATctcgagCGATGAGTGGTTTGGTGTAC-3 ′ (forward primer; Xho1-site in lower case characters) and 5 ′ -CTAT accggtGGCAGCGGCGGCGCGTC-3 ′ (backward primer; Age1-site in lower case characters). The C (in bold) in the backward primer corresponds to (21) bp of the MesP-1 coding region. After sequencing, this vector was used for electroporation of GSES cells and subsequent selection of stable clones.
Results
As the cardiovascular progenitor is highly represented by the MesP1 positive cell lineage, 7 we overexpressed the T-Box transcription factors Brachyury(T) and Eomesodermin to trace and analyse their effects on MesP1 expression. Stably transfected clones were verified via qRT-PCRs ( Figure 1A ). They showed normal colony growth when compared with controls when kept undifferentiated in LIF containing medium ( Figure 1B-D) , which is in agreement with our previous findings for MesP1 and Nkx2.5. our data support the importance of Brachyury(T) as opposed to Eomesodermin for the underlying events.
14 To further analyse the origin of the MesP1 expressing lineage, we took advantage of an ES cell line bearing an EGFP knock-in into the Brachyury(T) locus as previously described. 14, 18 We separated the EGFP positive cells from the negative population using FACS at Days 3 and 4 of differentiation ( Figure 3A ) and subsequently analysed these fractions for Brachyury(T), as well as MesP1 mRNA expression via qRT-PCR. Thereby, the values found in the EGFP negative fractions were normalized to 1. In the positive fractions Brachyury(T), mRNA was enriched over 200-fold at Day 3 and 60-fold at Day 4 of differentiation confirming the specificity of the EGFP labelling ( Figure 3B) . At both timepoints, likewise, MesP1 mRNA was highly accumulated when compared with the negative fractions, albeit showing a different time course: at Day 3 we observed an enrichment of 100-fold, which increased to over 550-fold at Day 4 ( Figure 3B ). These data suggest that the MesP1 positive fraction is mainly derived from the Brachyury(T) positive fraction in ES cells and its timely appearance is slightly delayed when compared with the latter. To verify the importance of these findings in vivo, we next performed in situ hybridizations for MesP1 and Brachyury(T) in gastrula stage mouse embryos confirming co-expression of MesP1 and Brachyury(T) in the mesoderm precursors of the primitive streak ( Figure 3C) .
To analyse the effect of loss of endogenous Brachyury(T) expression, we used an shRNA-based approach. This led to a reduction in Brachyury(T) mRNA to 20%. The knockdown cells showed also a dramatic loss of MesP1 mRNA as well as of the early cardiac differentiation factors, GATA-4 and Mef2c ( Figure 4A) . To extend the loss of function approach to an in vivo situation, we again performed in situ hybridizations using wildtype and Brachyury(T)-knock-out embryos. In the latter the absence of Brachyury(T) expression causes a severe reduction in MesP1 mRNA ( Figure 4B) . Therefore, development of functional cardiovascular precursors marked by robust MesP1 expression indeed appears to be dependent on precedent Brachyury(T) activity in ES cells as well as in vivo.
7,14
To investigate a potential direct regulation of MesP1 via Brachyury(T), we analysed the upstream region of the human MesP1 gene. Within the 23.4 kb region upstream of the translational start codon we found three T-binding elements, an additional minimal T responsive site and two related elements ( Figure 5A) . We subsequently performed EMSA assays confirming binding of Brachyury(T) to these consensus sites in vitro which was abolished after mutation of the AGGTGTGA motif ( Figure 5B ). As corresponding motifs are also present in the upstream region of the murine MesP1 gene ( Figure 5C ), we next performed chromatin immunoprecipitation using wild-type ES cells with subsequent qPCR. We thereby found enrichment of a region containing the AGGTGTGA motif ( Figure 5D ). To investigate whether Brachyury(T) is sufficient to activate the 23.4 kb MesP1 promoter fragment, we isolated this region and cloned it into pEGFP ( Figure 6 ). We transiently Figure 6 shows that dsRed positive Brachyury(T) expressing cells as opposed to dsRed positive controls do activate the promoter fragment resulting in green fluorescence correlating with the activation of endogenous MesP1 expression as shown above (Figure 2A ).
Discussion
Since differentiating ES cell cultures contain only a few percent of beating cardiomyocytes, 19, 20 various efforts were undertaken over the last years in order to increase their numbers. At first these approaches relied on induction of cardiogenesis via use of exogenous stimulation methods: addition of retinoic acid to the murine embryonic stem cell culture enhanced the development of ventricular cardiomyocytes reflected by an increased expression of aMHC and MLC2v. 21 A comparable effect was achieved by stimulation with ascorbic acid 22 or cultivation under the influence of a low-frequency magnetic field. 23 In addition, enhanced differentiation of pacemakerlike cardiomyocytes expressing Cx40, Cx45, and typical transmembranous action potentials was induced by exposure of murine ES cells to endothelin-1. 24 In human embryonic stem cell cultures beating cardiomyocytes can be increased by co-culture with endodermal END2 cells 25 via an unknown mechanism as well as by the addition of SB203580, a specific p38 MAP kinase inhibitor. 26 These attempts all provided promising results, but greatly lack mechanistic analyses of the underlying signalling pathways and, therefore, await further investigation. Recently, we and others have shown on the molecular level that the bHLH transcription factor MesP1 induces key genes leading to the initiation of cardiovasculogenesis in stem cells and vertebrate embryos. 7 -9 Subsequently, in an approach of 'genetic forward programming', we demonstrated that Nkx2.5 similar to MesP1 is sufficient to enhance cardiogenesis in embryonic stem cells. 10 Yet, in the resulting cardiomyocytic lineage MesP1 predominantly led to early/intermediate type cardiomyocytes, whereas Nkx2.5 yielded preferentially differentiated ventricular cells. 10 To better understand the underlying events, we now have analysed transcription factors potentially upstream of MesP1 and, therefore, upstream of cardiovascular induction. With respect to the origin of cardiovascular precursors in ES cells Eomes and explicitly not Brachyury(T) had been described to be required for their generation by Izumi et al. 13 In contrast Kattman et al.
14 postulated a population double positive for Brachyury(T) and Flk-1/VEGFR2. Our findings described here and generated from independent ES cell lines, murine embryos and various in vitro experiments support the latter: we found MesP1 mRNA expression highly induced in Brachyury(T) programmed ES cells (Figure 2A ) reflected in earlier appearing as well as 5-10-fold enriched beating areas ( Figure 2B , Supplementary material online, Movies 1 -3 ). Yet, we did not observe these phenomena in Eomesodermin programmed cells (Figure 2A ) which made this factor unlikely to be a direct regulator of the MesP1-driven cardiovasculogenic pathways. Importantly, as opposed to the work from the above-mentioned groups, we used a number of different experimental settings besides our overexpression approach in order to verify our findings. These include ES cells bearing an EGFP knock-in within the Brachyury(T) locus, which had already been used by Kattman et al. 14 The slightly delayed, yet high enrichment of MesP1 message in the Brachyury(T) positive fraction in this cell line ( Figure 3A and B), clearly confirms that the MesP1 expressing cells are greatly derived from the Brachyury(T) positive fraction in ES cells. Thereby, the delayed decrease in Brachyury promoter-driven EGFP protein from Day 3 to 4 (18 vs. 12% positive cells; Figure 3A ), when compared with the more dramatic decrease in Brachyury mRNA enrichment (.200-fold vs. 60-fold) in the EGFP positive fraction, most probably arises from the very high stability of EGFP protein within the cells with a half-life of 26 h. Additionally, using murine embryos we showed that the processes in ES cells actually reflect the in vivo situation, where MesP1 and Brachyury(T) are co-expressed in the mesodermal cells of the primitive streak ( Figure 3C ). In addition, reverse experiments in ES cells knocking down Brachyury(T) led to a drastic loss of MesP1 mRNA, as well as of mRNAs encoding early cardiac factors ( Figure 4A) . Likewise, these observations are reflected in vivo where Brachyury(T)-knockout embryos suffer severe reduction in MesP1 mRNA ( Figure 4B) . In summary, development of functional cardiovascular precursor cells marked by robust MesP1 expression indeed appears to be dependent on precedent Brachyury(T) activity in ES cells as well as in vivo supporting the work of Kattman et al.
14
Relying on this basis we investigated a potential direct regulation of MesP1 via Brachyury(T) , which had been indicated in silico via three T responsive consensus elements, as well an additional minimal T responsive site and two related elements in a 3.4 kb region 5 ′ upstream of the start codon highly conserved between human and mouse ( Figure 5A and C ). Again in three different sets of experiments comprising EMSAs, ChIP, and transactivation assays, we show binding of Brachyury(T) at a region containing multiple AGGTGTGA consensus motifs ( Figure 5B and D) . The high specificity of the in vitro binding (EMSA; Figure 5B ) is underlined by the fact that even a 100-fold excess of the unlabelled unspecific probe (mutated in five out of 10 bases) over the labelled specific DNA, at best marginally reduces the signal (lane 3), whereas it is totally abolished via a 100-fold excess of specific unlabelled probe (lane 2). The specificity is further underlined in the 'Supershift'-sample adding an antibody directed against Brachyury(T) (lane 4). In addition, we confirmed these finding in vivo demonstrating an activation of the 3.4 kb promoter fragment via Brachyury(T) ( Figure 6 ). Taken together, we show that the MesP1 promoter is directly induced via Brachyury(T) and is suitable to mark the long sought common cardiovascular precursor cell from pluripotent stem cells. 27,28 -35 For any future application in vivo as well as in vitro (e.g. for pharmacological tests), the availability of specific cardiomyocytic subtypes will be crucial. Highly innovative approaches, such as reseeding whole decellularized hearts, will likely require these early/intermediate multipotent cells to reconstitute the whole myocardium. 36 On the other hand, direct cell transplantation may rather be dependent on differentiated ventricular cells e.g. to repair a typical infarction. 10 We have recently shown that MesP1-based forward programming predominantly led to 60% early/intermediate type multipotent cardiomyocytes, whereas Nkx2.5 yielded 80% differentiated ventricular cells. 10 These findings relied on careful single cell patch clamping and pharmacological analyses, as well as funny channel (HCN-channel) density measurements; the latter representing a major determinant to distinguish between pacemaker cells and early/intermediate cardiomyocytes. 7, 10 Overall, this reflected the actual functionality of the cells.
We will now extend this approach to cells isolated using the MesP1 promoter transferred to our previously described DCD4-based MACS purification protocol. 37 Taking into account the key position of MesP1 at the top of the cardiovascular signalling cascades, we thereby expect to further increase the yields of early/intermediate type cardiomyocytes 38, 39, 10 as well as endothelial cells and smooth muscle cells characteristic for MesP1 programmed ES cell differentiation. 7, 10 Our work may become a prerequisite for the achievement of high yields of valuable cardiovasculogenic cells for tissue engineering, 40,41, as well as for pharmacological testing in vitro. This applies to the use of pluripotent stem cell-derived, as well as the recently described directly reprogrammed cardiovascular cell types. 6 
Supplementary material
Supplementary material is available at Cardiovascular Research online.
